Neuren Pharmaceuticals
Neuren Pharmaceuticals Ltd is an Australian biopharmaceutical company focused on the development of novel therapies for the treatment of serious neurological disorders characterized by neurodegeneration and neurodevelopmental delays, prominently featuring trofinetide (marketed as Daybue), a breakthrough treatment for Rett syndrome. The company conducts clinical research and pharmaceutical development for rare pediatric and neurological conditions, utilizing strategic commercial partnerships for global distribution. Its core business operations encompass biopharmaceutical research, clinical trial execution, drug formulation development, and commercial licensing management. Revenue is derived primarily from commercial product sales milestones, royalties on pharmaceutical sales, and licensing agreement fees. Neuren Pharmaceuticals holds a pioneering market position in rare neurological disease therapeutics. The company is headquartered in Melbourne, Victoria, Australia, and its shares trade on the Australian Securities Exchange.
7 of the funds FundTelligence covers report a position in Neuren Pharmaceuticals.
- Legal name
- Neuren Pharmaceuticals Ltd
- Sector
- Health Care
- Country
- Australia
- Funds holding it
- 7
Funds holding Neuren Pharmaceuticals
- SEB Nordamerikafond Små och Medelstora Bolag — SEB · 1.0 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.29 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.2 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.1 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.08 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.07 % (partially disclosed portfolio, June 2026)
- SEB Active 20 — SEB · 0.01 % (full portfolio disclosed, June 2026)